for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Atreca Inc

BCEL.OQ

Latest Trade

12.68USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

9.51

 - 

29.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.68
Open
--
Volume
--
3M AVG Volume
7.22
Today's High
--
Today's Low
--
52 Week High
29.23
52 Week Low
9.51
Shares Out (MIL)
36.03
Market Cap (MIL)
394.27
Forward P/E
-4.97
Dividend (Yield %)
--

Latest Developments

More

Atreca Inc Files Prospectus On Resale Of Up To 9.5 Million Class A Stock By Selling Stockholders

Atreca Inc Entered Into A Common Stock Sales Agreement For Up To $100 Million

Atreca Posts Q2 Loss Per Share Of $0.71

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Atreca Inc

Atreca, Inc. is a biotechnology company. The Company is engaged in developing therapeutics drawn from human immune responses, including anti-cancer immune responses. Its portfolio programs are focused on applications in cancer treatment. The Company’s lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using our discovery platform. The Company's Immune Repertoire Capture (IRC) technology, which enables us to accurately reconstruct the original antibody sequences from a single B cell in parallel with other B cells in the sample. Its IRC tracks the co-expression of genes from the same single cell and TCRs are recovered. IRC generates sequence information from the beginning of signal sequences through constant regions of immunoglobulins, delivering variable domains and isotype information.

Industry

Biotechnology & Drugs

Contact Info

450 East Jamie Court

SOUTH SAN FRANCISCO, CA

94080

United States

+1.650.5952595

http://www.atreca.com/

Executive Leadership

Brian G. Atwood

Independent Chairman of the Board

John A. Orwin

President, Chief Executive Officer, Director

Herbert C. Cross

Chief Financial Officer

Norman Michael Greenberg

Chief Scientific Officer

Courtney J. Phillips

General Counsel, Corporate Secretary

Key Stats

1.56 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-4.260

2020(E)

-2.704
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.46
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.05
LT Debt To Equity (MRQ)
0.02
Return on Investment (TTM)
-40.61
Return on Equity (TTM)
-38.98

Latest News

Latest News

BRIEF-Atreca And Xencor Enter Strategic Collaboration To Discover, Develop And Commercialize Novel T Cell Engaging Bispecific Antibodies

* ATRECA AND XENCOR ENTER STRATEGIC COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NOVEL T CELL ENGAGING BISPECIFIC ANTIBODIES Source text for Eikon: Further company coverage:

BRIEF-Xencor And Atreca Enter Strategic Collaboration To Discover, Develop And Commercialize Novel T Cell Engaging Bispecific Antibodies

* XENCOR AND ATRECA ENTER STRATEGIC COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NOVEL T CELL ENGAGING BISPECIFIC ANTIBODIES

BRIEF-Atreca Inc Files For Mixed Shelf Of Up To $300 Million

* ATRECA INC FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING Further company coverage:

BRIEF-Atreca Files For Shelf Of Up To 9.5 Million Shares Of Class A Common Stock By Selling Stockholders

* ATRECA INC FILES FOR SHELF OF UP TO 9.5 MILLION SHARES OF CLASS A COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Further company coverage:

BRIEF-Atreca Q1 Loss Per Share $0.73

* ATRECA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

BRIEF-IGM Biosciences, Atreca, Beigene To Collaborate To Help Address Covid-19

* IGM BIOSCIENCES INC - ATRECA, INC. BEIGENE, LTD. AND IGM BIOSCIENCES, INC. ANNOUNCED THEIR PLANS TO COLLABORATE TO HELP ADDRESS COVID-19 PANDEMIC

BRIEF-Atreca Reports Q4 Loss Per Share Of $0.72

* ATRECA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Atreca Announces First Patient Dosed In Phase 1B Clinical Trial Of ATRC-101

* ATRECA ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B CLINICAL TRIAL OF ATRC-101 IN PATIENTS WITH SELECT SOLID TUMORS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up